Current role of gemcitabine in the treatment of Hodgkin lymphoma

References

• Horning S J. Risk, cure and complications in advanced Hodgkin disease. ASH Educ Prog 2007; 2007: 197–203
   Google Scholar
• Linch D C, Winfield D, Goldstone A H, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Armitage J O, Bierman P J, Vose J M, Anderson J R, Weisenburger D D, Kessinger A, et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991; 91: 605–611
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10: 593–595
   PubMed Web of Science ®Google Scholar
• Ferme C, Bastion Y, Lepage E, Berger F, Brice P, Morel P, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995; 6: 543–549
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M G, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580–586
   PubMed Web of Science ®Google Scholar
• Colwill R, Crump M, Couture F, Danish R, Stewart A K, Sutton D M, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13: 396–402
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Searcy C E, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3–15
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615–2619
   PubMed Web of Science ®Google Scholar
• Venkatesh H, Di Bella N, Flynn T P, Vellek M J, Boehm K A, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004; 5: 110–115
   PubMedGoogle Scholar
• Zinzani P L, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85: 926–929
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003; 14: 1762–1767
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106: 353–360
   PubMed Web of Science ®Google Scholar
• Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 2005; 92: 1352–1357
   PubMed Web of Science ®Google Scholar
• Bartlett N, Niedzwiecki D, Johnson J, Friedberg J, Johnson K, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071–1079
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35–41
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez M A, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310–314
   PubMed Web of Science ®Google Scholar
• Jones R J, Lin L, Gocke C, Hensley K, Siedner M, Barber J P, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). Blood 2006; 108: 470a
   Google Scholar
• Younes A, Fayad L Y, Goy A, McLaughlin P, Pro B, Romaguera J, et al. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival in all international prognostic score groups. Blood 2006; 108: 2742a
   Google Scholar
• Oki Y, Pro B, Fayad L E, Romaguera J, Samaniego F, Hagemeister F, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831–836
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Kelly J, Voci S, Marquis D, Rich L, Rossi R, et al. Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL). Blood 2007; 110: 2325a
   Google Scholar
• Arai S, Negrin R, Blume K, Johnston L, Laport G, Lowsky R, et al. A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. J Clin Oncol 2005; 23: 6651a
   Google Scholar
• Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005; 46: 1017–1022
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Kewalramani T, Nimer S D, Gonzalez M, Zelenetz A D, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645–652
   PubMed Web of Science ®Google Scholar
• Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006; 37: 277–282
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant 2007; 40: 1019–1025
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Neuberg D, Kim H, Miyata S, McCauley M, Fisher D C, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003; 98: 978–982
   PubMed Web of Science ®Google Scholar
• Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailander V, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22: 2424–2429
   PubMed Web of Science ®Google Scholar
• Belknap S M, Slimack N, Kuzel T, Carson K R, Yarnold P R, Raisch D W, et al. Severe gemcitabine-associated lung injury in Hodgkin's disease and other cancers: reporting quality and clinical characteristics of cases reported in the medical literature and to the FDA. Blood 2004; 104: 3145a
   Google Scholar
• Straus D, LaCase A, Juweid M, Kostakogolu L, Hall N, Johnson J, et al. Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203. Blood 2007; 110: 214a
   Google Scholar